Potential Targets for Pharmacologic Therapies for Prevention of PTA

2015 ◽  
pp. 331-342 ◽  
Author(s):  
Cecilia Pascual-Garrido ◽  
Susan Chubinskaya
Keyword(s):  
Pharmacologic Therapies

Pharmacologic therapies for perioperative cerebral protection against neurologic or neurocognitive deficits

2007 ◽  
Author(s):  
Federico Bilotta ◽  
Adrian W Gelb ◽  
Sulpicio G Soriano ◽  
Qiaoheng Wang ◽  
Francesca P Paoloni ◽  
...  
Keyword(s):  
Cerebral Protection ◽  
Neurocognitive Deficits ◽  
Pharmacologic Therapies

Cardiovascular Pharmacologic Therapies Under Investigation

2012 ◽  
Vol 20 (3) ◽  
pp. 102-110 ◽  
Author(s):  
William H. Frishman ◽  
Kalyana Pallerla
Keyword(s):  
Pharmacologic Therapies

Pharmacologic therapies after myocardial infarction

1996 ◽  
Vol 101 (4) ◽  
pp. 61S-70S ◽  
Author(s):  
Elliot Rapaport ◽  
Mihai Gheorghiade
Keyword(s):  
Myocardial Infarction ◽  
Pharmacologic Therapies

Systemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline

2017 ◽  
Vol 166 (7) ◽  
pp. 480 ◽  
Author(s):  
Roger Chou ◽  
Richard Deyo ◽  
Janna Friedly ◽  
Andrea Skelly ◽  
Melissa Weimer ◽  
...  
Keyword(s):  
Systematic Review ◽  
Low Back Pain ◽  
Back Pain ◽  
Clinical Practice ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Low Back ◽  
Pharmacologic Therapies

Practice-based Outcomes Research: Crucial, Feasible, and Neglected

PEDIATRICS ◽  
1996 ◽  
Vol 97 (1) ◽  
pp. 113-114
Author(s):  
Jerry Avorn
Keyword(s):  
Health Care ◽  
Clinical Outcomes ◽  
Outcomes Research ◽  
Cost Containment ◽  
American Health Care System ◽  
American Health Care ◽  
Experimental Subjects ◽  
Contemporary Medicine ◽  
Pharmacologic Therapies

The article from the Vermont-Oxford Neonatal Network1 in this issue of Pediatrics comparing two surfactant preparations represents an important case study of a central issue in contemporary medicine: the need for rigorous, even-handed evaluation of competing therapies. Even at a time in which patients and payers are expecting ever-higher standards for clinical outcomes, and policymakers and insurers are demanding more and more stringent cost containment, the American health care system lacks a coherent mechanism for assembling and analyzing the data needed to meet these goals. For pharmacologic therapies, the Food and Drug Administration (FDA) prefers that mew agents be tested against placebos whenever possible, unless this would result in harm to experimental subjects.

scholarly journals Patients' anxiety before cardiac catheterization

2010 ◽  
Vol 8 (4) ◽  
pp. 483-487 ◽  
Author(s):  
Leandro Loureiro Buzatto ◽  
Suely Sueko Viski Zanei
Keyword(s):  
Cardiac Catheterization ◽  
Patient Information ◽  
Scientific Publications ◽  
Patient Understanding ◽  
Post Procedure ◽  
Long Time ◽  
On Line ◽  
First Time ◽  
Multiprofessional Approach ◽  
Pharmacologic Therapies

ABSTRACT Objective: To identify researches related to anxiety and strategies to reduce it in patients who are in the pre-cardiac catheterization period. Methods: A bibliographic research was carried out in the on line databases of PubMed, MedLine, CINAHL, LILACS and SciELO, from 1997 to 2009 in MedLine and from 1999 to 2009 in the others databases. The boolean expressions “and” and “or” has been used with the descriptors in Portuguese and in English. The inclusion of discerning was related about the presence, level and workable of the anxiety from the period of pre-cardiac catheterization. Results: Coping most of 17 researches selected were in American scientific publications, with experimental-descriptive studies. The possibilities of intercurrence and/or complications during and post-procedure, diagnostic, possibility of bad prognostic, being alone during the waiting, the first time submission the procedure, lost information and/or orientation and long time waiting could cause anxiety in pre-cardiac catheterization. Maintenance of escort and family alongside the patient, information adapted to the patient understanding level, overcoming traumas and difficulties with a multiprofessional approach, pharmacologic and non pharmacologic therapies were strategies to reduce the anxiety. Conclusions: The nurses are responsible to provide a humanized assistance to offer a fast recuperation, minimize traumas of the hospitalization and the procedure. The knowledge of the causes and the strategies are fundamental to reduce the level of anxiety in pre-catheterization cardiac.

Development of Tics in a Thirteen-Year-Old Male Following Atomoxetine Use

CNS Spectrums ◽  
2008 ◽  
Vol 13 (4) ◽  
pp. 301-303 ◽  
Author(s):  
Jessica Sears ◽  
Nitin C. Patel
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Single Dose ◽  
Tourette Syndrome ◽  
Attention Deficit ◽  
Interventional Therapy ◽  
Prior History ◽  
Unique Case ◽  
Hyperactivity Disorder ◽  
History Of ◽  
Pharmacologic Therapies

ABSTRACTTics and Tourette syndrome are common comorbidities of patients diagnosed with attention-deficit/hyperactivity disorder (ADHD). One of the mainstay pharmacologic therapies for ADHD has been stimulants. However, this class of drugs has been associated with tic exacerbations, thus limiting their utility in this patients subgroup. Atomoxetine has been explored as an alternative treatment as one of the few non-stimulants available to treat ADHD. Early data identifies atomoxetine's influence on Tourette symptomatology to be not merely equivocal but potentially suppressive in the manifestation of tics. There are, however, case studies describing patients experiencing recurrences of tics following treatment with atomoxetine. We present a unique case of a patient, without any prior history of a movement disorder, who developed tics following a single dose of atomoxetine that did not improve until interventional therapy was initiated.

Sign in / Sign up

Export Citation Format

Share Document